David E.Matrix Capital Mana... Net Worth

The estimated Net Worth of David E.Matrix Capital Mana... is at least $166 Million dollars as of 8 March 2021. David Mana owns over 806,000 units of Adaptive Biotechnologies stock worth over $54,036,905 and over the last 5 years David sold ADPT stock worth over $112,231,940.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

David Mana ADPT stock SEC Form 4 insiders trading

David has made over 2 trades of the Adaptive Biotechnologies stock since 2020, according to the Form 4 filled with the SEC. Most recently David sold 806,000 units of ADPT stock worth $32,231,940 on 8 March 2021.

The largest trade David's ever made was selling 2,000,000 units of Adaptive Biotechnologies stock on 20 July 2020 worth over $80,000,000. On average, David trades about 701,500 units every 58 days since 2020. As of 8 March 2021 David still owns at least 12,309,090 units of Adaptive Biotechnologies stock.

You can see the complete history of David Mana stock trades at the bottom of the page.

Insiders trading at Adaptive Biotechnologies

Over the last 5 years, insiders at Adaptive Biotechnologies have traded over $685,617,014 worth of Adaptive Biotechnologies stock. The most active insiders traders include Global Investors Lp Viking ..., Global Performance Llc Viki..., and Kevin T Conroy. On average, Adaptive Biotechnologies executives and independent directors trade stock every 6 days with the average trade being worth of $368,167. The most recent stock trade was executed by Stacy L Taylor on 22 August 2024, trading 26,922 units of ADPT stock currently worth $121,149.

What does Adaptive Biotechnologies do?

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Complete history of David Mana stock trades at Adaptive Biotechnologies

Adaptive Biotechnologies executives and stock owners

Adaptive Biotechnologies executives and other stock owners filed with the SEC include:

• Lance Baldo,
  Chief Medical Officer
• Chad Robins,
  Executive Chairman, Chief Executive Officer, Co-Founder
• Harlan Robins,
  Co-Founder, Chief Scientific Officer
• Julie Rubinstein,
  President
• Chad M. Robins M.B.A, M.B.A.,
  Co-Founder, CEO & Chairman
• Michelle Griffin,
  Independent Director
• Kevin Conroy,
  Independent Director
• Dr. Harlan S. Robins Ph.D.,
  Co-Founder & Chief Scientific Officer
• Julie Rubinstein,
  Pres
• Chad M. Cohen CPA,
  Chief Financial Officer
• Dr. Mark Adams,
  COO & CTO
• Peter Neupert,
  Lead Independent Director
• Eric Dobmeier,
  Independent Director
• Michael Pellini,
  Independent Director
• Robert Hershberg,
  Independent Director
• David Goel,
  Independent Director
• Sean Nolan,
  Chief Technical Officer
• Mark Adams,
  Chief Technical Officer
• Charles Snag,
  Senior Vice President - Clinical Diagnostics
• Jyoti Palaniappan,
  Senior Vice President - Clinical Diagnostics immunoSEQ Dx
• Nancy Hill,
  Senior Vice President - Operations
• Sharon Benzeno,
  Senior Vice President - Drug Recovery
• Stacy Taylor,
  Senior Vice President, General Counsel
• Francis Lo,
  Chief People Officer
• Chad Cohen,
  Chief Financial Officer
• Francis T. Lo,
  Chief People Officer
• Stacy L. Taylor,
  Sr. VP & Gen. Counsel
• Karina Calzadilla,
  VP of Investor Relations
• Kyle Piskel,
  Principal Accounting Officer
• Christopher Carlson Ph.D.,
  Founder
• Charles Sang,
  SVP, External Affairs
• Global Investors Lpviking G...,
  
• Andris A Zoltners,
  Director
• David E.Matrix Capital Mana...,
  
• Global Performance Llc Viki...,
  
• Susan Bobulsky,
  Chief Commercial Officer, MRD
• Katey Einterz Owen,
  Director
• Leslie Trigg,
  Director
• Henning Thorsen,
  SVP, Commercial Operations
• Kyle Piskel,
  Chief Financial Officer
• Nitin Sood,
  Chief Commercial Officer, MRD
• Tycho Peterson,
  Chief Financial Officer